MRK vs COR Stock Comparison

Merck and Cencora Prices as of Nov 13, 2026 Peers: Industry group
MRK Merck & Co., Inc.
$147.78 +0.3% 1M +59.0% 1Y
Market cap
$357.22B
P/E
145.6x
Revenue (TTM)
$67.38B
Div. yield
0.02%
Pharmaceuticals Healthcare
4 wins
COR Cencora, Inc.
$359.02 +6.8% 1M -1.8% 1Y
Market cap
$69.10B
P/E
22.6x
Revenue (TTM)
$337.40B
Div. yield
–
Drug Distribution Healthcare
4 wins

Head to Head

8 decided of 12

Merck leads on 4 of the 12 questions below (Merck 4, Cencora 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMRKCORLeader
Larger companyMarket capitalisation $357.22B $69.10B MRK
Cheaper on earningsLower P/E, profitable companies only 145.6x 22.6x COR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 56.6x 18.8x COR
Faster revenue growthRevenue growth, trailing twelve months +4.9% +5.0% COR
More profitableNet margin, trailing twelve months 3.6% — –
Better return on capitalReturn on invested capital 2.5% — –
Less leveragedLower net debt / EBITDA 3.6x — –
Higher dividend yieldTrailing dividend yield 0.02% 0.00% –
Better 1-year returnPrice return, last 12 months +59.0% -1.8% MRK
Better 5-year returnAnnualised price return, 5 years +12.0%/yr +23.4%/yr COR
Less volatileAnnualised volatility, 1 year 29.6% 33.4% MRK
Higher overall scoreMean of the five percentile scores vs peers 61/100 56/100 MRK

Percentile Scorecard

MRKCOR

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMRKCOR
Valuation 85 #97 of 660 54 #13 of 27
Growth 30 #434 of 619 64 #10 of 26
Profitability 90 #59 of 595 64 #10 of 26
Financial Health 21 #538 of 683 –
Shareholder Returns 79 #98 of 459 41 #11 of 18
Overall 61 56
  • MRK ranked among 695 companies in Pharmaceuticals and Biotechnology
  • COR ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMRKCORSPY
1 month +0.3%+6.8% -2.0%
3 months +8.8%+14.4% -2.8%
6 months +32.7%+39.3% +2.0%
Year to date +40.4%+6.3% +10.6%
1 year +59.0%-1.8% +12.2%
3 years +44.6%+84.7% +68.1%
3 years, per year +13.1%+22.7% +18.9%
5 years +75.9%+186.4% +61.4%
5 years, per year +12.0%+23.4% +10.1%
10 years +131.1%+354.9% +248.5%
10 years, per year +8.7%+16.4% +13.3%

Risk

MeasureMRKCORSPY
Volatility, 1Y 29.6%33.4% 13.6%
Downside volatility, 1Y 24.1%40.0% 13.9%
Beta vs S&P 500, 1Y 0.200.05 1.00
Return / volatility, 1Y 1.99-0.05 0.90
Max drawdown, 5Y -44.7%-32.6% -25.4%
From 52-week high -5.5%-4.2% -3.2%
52-week high $156.45$374.75 $779.14
52-week low $92.86$252.74 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMRKCOR
P/E now vs peer median 148.7xmedian 17.0x 22.6xmedian 25.2x
P/S now vs peer median 5.4xmedian 8.4x 0.2xmedian 0.4x
EV/EBITDA now vs peer median 33.7xmedian 14.6x —median 14.5x
P/FCF now vs peer median 24.7xmedian 19.0x 14.5xmedian 16.5x
P/B now vs peer median 8.1xmedian 2.0x 18.6xmedian 2.7x
PEG now vs peer median -8.16median 0.43 —median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMRKCOR
Revenue $67.38B $337.40B
Gross profit $48.35B $13.87B
Operating income $4.76B $3.93B
Net income $2.45B $3.51B
Free cash flow $14.75B –
R&D $30.76B –
EPS (diluted) $0.99 –
Cash & equivalents $9.55B $4.88B
Total debt $53.78B –
Shares (diluted) 2.48B 193.94M
Enterprise value $320.16B $69.10B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMRKCOR
P/E 148.7x 22.6x
P/FCF 24.7x 14.5x
P/Operating cash flow 19.5x 14.3x
P/S 5.4x 0.2x
P/B 8.1x 18.6x
P/Tangible book 17.8x 18.6x
EV/EBITDA 33.7x –
EV/EBIT 85.8x –
EV/Revenue 6.1x 0.2x
EV/FCF 27.7x –
EV/Operating cash flow 21.8x 14.3x
PEG (3Y EPS CAGR) -8.16 –

Growth

14 metrics
MetricMRKCOR
Revenue growth (1Y) 4.9% 5.0%
Revenue CAGR (3Y) 4.3% 8.8%
Gross profit growth (1Y) -2.5% 20.8%
Gross profit CAGR (3Y) 3.8% 15.7%
Operating income growth (1Y) -78.2% 49.5%
Operating income CAGR (3Y) -13.9% 18.9%
Net income growth (1Y) -87.1% 124.0%
Net income CAGR (3Y) -19.1% 26.3%
EPS growth (1Y) -87.0% –
EPS CAGR (3Y) -18.2% –
Operating cash flow growth (1Y) 9.6% 23.6%
Operating cash flow CAGR (3Y) 2.9% 7.0%
Free cash flow growth (1Y) 13.0% –
Free cash flow CAGR (3Y) 3.8% –

Profitability

14 metrics
MetricMRKCOR
Gross margin 71.8% –
EBITDA margin 18.0% –
Operating margin 7.1% –
Pretax margin 7.1% –
Net margin 3.6% –
FCF margin 21.9% –
Operating cash flow margin 27.8% 1.4%
Return on equity 5.6% 101.2%
Return on assets 1.9% 4.1%
Return on invested capital 2.5% –
Return on capital employed 4.6% –
Asset turnover 0.5x 3.9x
Cash conversion (OCF / net income) 7.6x 1.4x
Stock comp / revenue 1.6% –

Financial Health

11 metrics
MetricMRKCOR
Debt / assets 40.5% –
Debt / equity 1.2x –
Net debt / EBITDA 3.6x –
Debt / FCF 3.6x –
Liabilities / assets 66.1% –
Equity / assets 33.9% 4.2%
Interest coverage – –
Current ratio 1.4x 0.9x
Quick ratio 0.8x –
Cash ratio 0.3x –
Altman Z-score 3.90 –

Shareholder Returns

7 metrics
MetricMRKCOR
Dividend yield 2.3% 0.9%
Net buyback yield 0.8% –
Shareholder yield 3.1% 0.9%
Payout ratio (earnings) 341.6% –
Payout ratio (FCF) 56.7% –
Dividend growth (1Y) 3.2% –
Dividend CAGR (3Y) 4.4% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMRKCOR
Forward P/E 56.6xFY2026 18.8xFY2027
EPS, next fiscal year $2.61FY2026 $19.07FY2027
EPS growth, next FY -70.9%FY2026 +6.1%FY2027
EPS growth, the year after +228.7% +17.4%
Revenue, next fiscal year $69.66BFY2026 $328.27BFY2027
Revenue growth, next FY +7.2%FY2026 -2.7%FY2027
Revenue growth, the year after -4.6% +19.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMRKCOR
Held by institutions 79.9% 94.7%
Institutions holding 3,804 1,345
Change in shares held, QoQ +2.6% +15.7%
Institutions buying 1,844 542
Institutions selling 1,469 612
Buyers to sellers 1.26 0.89

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MRKCOR
MRK 1.00 0.20
COR 0.20 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MRK and COR?

Merck (MRK) is the largest by market capitalisation: Merck (MRK) $357.22B, Cencora (COR) $69.10B.

Which stock is cheaper, MRK and COR?

Cencora (COR) trades on the lowest price-to-earnings ratio (Merck (MRK) 145.6x, Cencora (COR) 22.6x). On next year's consensus earnings, Cencora (COR) is cheapest (Merck (MRK) 56.6x, Cencora (COR) 18.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Cencora (COR) grew revenue fastest over the trailing twelve months: Merck (MRK) +4.9%, Cencora (COR) +5.0%.

Which stock has performed better?

Over the past year Merck (MRK) returned the most: Merck (MRK) +59.0%, Cencora (COR) -1.8%. Over five years, Cencora (COR) compounded fastest (Merck (MRK) +12.0%/yr, Cencora (COR) +23.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Merck (MRK) 0.02%, Cencora (COR) 0.00%. Cencora (COR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Merck (MRK) has been the steadiest (Merck (MRK) 29.6%, Cencora (COR) 33.4%). Volatility measures how widely the price swings, not the risk of the business.

Do MRK and COR move together?

Their daily returns over the past year have a correlation of 0.20, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, MRK and COR?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Merck (MRK) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.